Full name : Saltarelli Mario D
First name : Mario D
Mail : Annexon Bioscience
Zip Code :
City :
Country : USA
Email :
Phone :
Fax :
Website :
Directory :
| Title : Adaptive, Dose-finding Phase 2 Trial Evaluating the Safety and Efficacy of ABT-089 in Mild to Moderate Alzheimer Disease - Lenz_2015_Alzheimer.Dis.Assoc.Disord_29_192 |
| Author(s) : Lenz RA , Pritchett YL , Berry SM , Llano DA , Han S , Berry DA , Sadowsky CH , Abi-Saab WM , Saltarelli MD |
| Ref : Alzheimer Disease & Associated Disorders , 29 :192 , 2015 |
| Abstract : Lenz_2015_Alzheimer.Dis.Assoc.Disord_29_192 |
| ESTHER : Lenz_2015_Alzheimer.Dis.Assoc.Disord_29_192 |
| PubMedSearch : Lenz_2015_Alzheimer.Dis.Assoc.Disord_29_192 |
| PubMedID: 25973909 |
| Title : A randomized, double-blind, placebo-controlled phase 2 study of alpha4beta2 agonist ABT-894 in adults with ADHD - Bain_2013_Neuropsychopharmacology_38_405 |
| Author(s) : Bain EE , Robieson W , Pritchett Y , Garimella T , Abi-Saab WM , Apostol G , McGough JJ , Saltarelli MD |
| Ref : Neuropsychopharmacology , 38 :405 , 2013 |
| Abstract : Bain_2013_Neuropsychopharmacology_38_405 |
| ESTHER : Bain_2013_Neuropsychopharmacology_38_405 |
| PubMedSearch : Bain_2013_Neuropsychopharmacology_38_405 |
| PubMedID: 23032073 |
| Title : Efficacy and safety of the novel alpha(4)beta(2) neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit\/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study - Apostol_2012_Psychopharmacology.(Berl)_219_715 |
| Author(s) : Apostol G , Abi-Saab WM , Kratochvil CJ , Adler LA , Robieson WZ , Gault LM , Pritchett YL , Feifel D , Collins MA , Saltarelli MD |
| Ref : Psychopharmacology (Berl) , 219 :715 , 2012 |
| Abstract : Apostol_2012_Psychopharmacology.(Berl)_219_715 |
| ESTHER : Apostol_2012_Psychopharmacology.(Berl)_219_715 |
| PubMedSearch : Apostol_2012_Psychopharmacology.(Berl)_219_715 |
| PubMedID: 21748252 |
| Title : A randomized pilot study of the efficacy and safety of ABT-089, a novel alpha4beta2 neuronal nicotinic receptor agonist, in adults with attention-deficit\/hyperactivity disorder - Bain_2012_J.Clin.Psychiatry_73_783 |
| Author(s) : Bain EE , Apostol G , Sangal RB , Robieson WZ , McNeill DL , Abi-Saab WM , Saltarelli MD |
| Ref : J Clin Psychiatry , 73 :783 , 2012 |
| Abstract : Bain_2012_J.Clin.Psychiatry_73_783 |
| ESTHER : Bain_2012_J.Clin.Psychiatry_73_783 |
| PubMedSearch : Bain_2012_J.Clin.Psychiatry_73_783 |
| PubMedID: 22795204 |
| Title : The scopolamine model as a pharmacodynamic marker in early drug development - Lenz_2012_Psychopharmacology.(Berl)_220_97 |
| Author(s) : Lenz RA , Baker JD , Locke C , Rueter LE , Mohler EG , Wesnes K , Abi-Saab WM , Saltarelli MD |
| Ref : Psychopharmacology (Berl) , 220 :97 , 2012 |
| Abstract : Lenz_2012_Psychopharmacology.(Berl)_220_97 |
| ESTHER : Lenz_2012_Psychopharmacology.(Berl)_220_97 |
| PubMedSearch : Lenz_2012_Psychopharmacology.(Berl)_220_97 |
| PubMedID: 21901320 |
| Title : Safety and efficacy of ABT-089 in pediatric attention-deficit\/hyperactivity disorder: results from two randomized placebo-controlled clinical trials - Wilens_2011_J.Am.Acad.Child.Adolesc.Psychiatry_50_73 |
| Author(s) : Wilens TE , Gault LM , Childress A , Kratochvil CJ , Bensman L , Hall CM , Olson E , Robieson WZ , Garimella TS , Abi-Saab WM , Apostol G , Saltarelli MD |
| Ref : J Am Acad Child Adolesc Psychiatry , 50 :73 , 2011 |
| Abstract : Wilens_2011_J.Am.Acad.Child.Adolesc.Psychiatry_50_73 |
| ESTHER : Wilens_2011_J.Am.Acad.Child.Adolesc.Psychiatry_50_73 |
| PubMedSearch : Wilens_2011_J.Am.Acad.Child.Adolesc.Psychiatry_50_73 |
| PubMedID: 21156272 |
| Title : Poster: A randomized, double-blind, placebo-controlled Phase 2 study of alpha4\/beta2 agonist ABT-894 in adults with ADHD - |
| Author(s) : Bain EE , Robieson W , Garimella T , Abi-Saab WM , Apostol G , Saltarelli MD |
| Ref : Biochemical Pharmacology , 82 :1043 , 2011 |
| PubMedID: |